Revenue Breakdown
Composition ()
No data
Revenue Streams
Medpace Holdings Inc (MEDP) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Metabolic, accounting for 30.2% of total sales, equivalent to $199.26M. Other significant revenue streams include Oncology and Other. Understanding this composition is critical for investors evaluating how MEDP navigates market cycles within the Biotechnology & Medical Research industry.
Profitability & Margins
Evaluating the bottom line, Medpace Holdings Inc maintains a gross margin of 28.78%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 21.49%, while the net margin is 16.84%. These profitability ratios, combined with a Return on Equity (ROE) of 73.70%, provide a clear picture of how effectively MEDP converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, MEDP competes directly with industry leaders such as CAE and ULS. With a market capitalization of $16.61B, it holds a leading position in the sector. When comparing efficiency, MEDP's gross margin of 28.78% stands against CAE's 25.82% and ULS's 50.32%. Such benchmarking helps identify whether Medpace Holdings Inc is trading at a premium or discount relative to its financial performance.
